Research and Markets: Global Multiple Sclerosis (MS) Therapeutics Market 2012-2016: The Global MS Market Has Witnessed …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/jwg2ns/global_multiple) has announced the addition of the "Global Multiple Sclerosis (MS) Therapeutics Market 2012-2016" report to their offering.

The analysts forecast the Global Multiple Sclerosis (MS) Therapeutics market to grow at a CAGR of 3.16 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rising diagnosis and treatment rates. The Global MS Therapeutics market has also been witnessing the emergence of biomarkers. However, the lack of therapies available to manage the progression of the disease could pose a challenge to the growth of this market.

The key vendors dominating this space include Bayer HealthCare AG, Biogen Idec Inc., Merck Serono SA, Novartis AG, and Teva Pharmaceutical Industries Ltd.

The other vendors mentioned in this report are AB Science, Abbvie Inc., Active Biotech AB, Astra Zeneca plc, Glaxo Smith Kline plc, Glenmark Pharmaceuticals Ltd., Hoffmann-La Roche Inc., and Sanofi SA.

Commenting on the report, an analyst from the team said: Currently, there is an increase in the adoption of biomarkers that are 100 percent specific to RRMS conditions. The use of biomarkers proves to be a sensitive indicator of the slightest disease activity in MS patients. A highly specific protein biomarker for MS aids in quick and precise identification of patients with the disease, possibly before clinically relevant symptoms arise. Thus, the use of biomarkers helps prevent the significant neurodegeneration associated with the disease.

Regulus Therapeutics and Biogen Idec entered into a collaboration to identify blood-based microRNAs as biomarkers for MS. It is believed by both partners that microRNA biomarkers aid in the selection of ideal patient segments in clinical trials and also in monitoring disease progression or relapse.

According to the report, one of the main drivers is the increase in the diagnosis and treatment of MS. This is because of the usage of the latest revised McDonald diagnostic criteria in the treatment of MS. The McDonald diagnostic criteria consist of a combination of clinical, imaging, and paraclinical tests used in the diagnosis of MS. This latest revision has helped in improving the detection of the symptoms of the disease. A McDonald diagnostic criterion helps improve the sensitivity from around 46 percent to 74 percent. This indirectly aids in diagnosing MS more rapidly than in the early days.

Further, the report states that one of the major challenges in the market is the lack of therapies for the management of the progressive form of the disease. The patients under this category take only symptomatic treatment to improve their quality of life.

For more information visit http://www.researchandmarkets.com/research/jwg2ns/global_multiple

Read the rest here:
Research and Markets: Global Multiple Sclerosis (MS) Therapeutics Market 2012-2016: The Global MS Market Has Witnessed ...